Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer

Ciombor, 2013, Advances in the management of biliary tract cancers, Clin Adv Hematol Oncol, 11, 28 Saha, 2016, Forty-year trends in cholangiocarcinoma Incidence in the U.S.: intrahepatic disease on the rise, Oncologist, 21, 594, 10.1634/theoncologist.2015-0446 Lamarca, 2020, Molecular targeted therapies: ready for “prime time” in biliary tract cancer, J Hepatol, 73, 170, 10.1016/j.jhep.2020.03.007 Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 362, 1273, 10.1056/NEJMoa0908721 Banales, 2020, Cholangiocarcinoma 2020: the next horizon in mechanisms and management, Nat Rev Gastroenterol Hepatol, 17, 557, 10.1038/s41575-020-0310-z Goetze, 2015, Gallbladder carcinoma: prognostic factors and therapeutic options, World J Gastroenterol, 21, 12211, 10.3748/wjg.v21.i43.12211 Oneda, 2020, Biliary tract cancer: current medical treatment strategies, Cancers (Basel), 12, 1237, 10.3390/cancers12051237 Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study, J Clin Oncol, 38, 1, 10.1200/JCO.19.02105 Abou-Alfa, 2020, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Lancet Oncol, 21, 671, 10.1016/S1470-2045(20)30109-1 Abou-Alfa, 2020, Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol, 21, 796, 10.1016/S1470-2045(20)30157-1 Mizuno, 2020, Combined vascular resection for locally advanced perihilar cholangiocarcinoma, Ann Surg Wang, 2018, Endoscopic management of pancreatobiliary neoplasms, Gastroenterology, 154, 1947, 10.1053/j.gastro.2017.11.295 Heimbach, 2011, Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination, HPB (Oxford), 13, 356, 10.1111/j.1477-2574.2011.00298.x Kato, 2017, Brushing the distal biliary stricture in the surrounding of the papilla increased the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis: a retrospective study using propensity score analysis, United European Gastroenterol J, 5, 1015, 10.1177/2050640617694279 Corcoran, 2018, Application of cell-free DNA analysis to cancer treatment, N Engl J Med, 379, 1754, 10.1056/NEJMra1706174 Sun, 2019, Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin, Genome Res, 29, 418, 10.1101/gr.242719.118 Wang, 2018, Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial, Lancet Respir Med, 6, 681, 10.1016/S2213-2600(18)30264-9 Merker, 2018, Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review, J Clin Oncol, 36, 1631, 10.1200/JCO.2017.76.8671 Li, 2018, Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy, Ann Oncol, 29, 945, 10.1093/annonc/mdy009 Tong, 2019, Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer, Theranostics, 9, 5532, 10.7150/thno.34070 Fujii, 2017, Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers, Clin Cancer Res, 23, 3657, 10.1158/1078-0432.CCR-16-2592 Voigtländer, 2020, Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma, J Biomed Sci, 27, 13, 10.1186/s12929-019-0599-5 Li, 2014, Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis, Hepatology, 60, 896, 10.1002/hep.27050 Shen, 2019, Bile cell-free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer, Oncol Rep, 42, 549 Ying, 2019, Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases, Cancer Biol Ther, 20, 562, 10.1080/15384047.2018.1538614 Cai, 2020, Detection of microsatellite instability from circulating tumor DNA by targeted deep sequencing, J Mol Diagn, 22, 860, 10.1016/j.jmoldx.2020.04.210 Zhu, 2018, A novel and reliable method to detect microsatellite instability in colorectal cancer by next-generation sequencing, J Mol Diagn, 20, 225, 10.1016/j.jmoldx.2017.11.007 Lim, 2003, Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings, AJR Am J Roentgenol, 181, 819, 10.2214/ajr.181.3.1810819 Tian, 2020, Comprehensive genomic profile of cholangiocarcinomas in China, Oncol Lett, 19, 3101 Borger, 2012, Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping, Oncologist, 17, 72, 10.1634/theoncologist.2011-0386 Wang, 2013, Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas, Oncogene, 32, 3091, 10.1038/onc.2012.315 Graham, 2014, Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma, Hum Pathol, 45, 1630, 10.1016/j.humpath.2014.03.014 Arai, 2014, Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology, 59, 1427, 10.1002/hep.26890 Demols, 2020, NTRK gene fusions in biliary tract cancers, J Clin Oncol, 38, 574, 10.1200/JCO.2020.38.4_suppl.574